Bohn, Manfred (Hofheim, DE)
Kraemer, Karl Theodor (Langen, DE)
Markus, Astrid (Liederbach, DE)

09/068894

03/28/2006

09/16/1997

Download PDF 7018656       PDF help

Click for automatic bibliography generation

Aventis Pharma Deutschland GmbH (Frankfurt am Main, DE)

424/487

424/405, 424/404, 514/944

A01N25/04; A61K9/10

424/488, 514/944, 424/404-5, 424/484-86, 424/487, 514/858

5066484	Nail enamels containing glyceryl, glycol or citrate esters	November, 1991	Castrogiovanni et al.
5071639	Nail cosmetic composition	December, 1991	Soyama et al.
5120530	Antimicotic nail varnish containing amorolfine in quaternary ammonium acrylic copolymer	June, 1992	Ferro et al.
5132107	Two-phase cleansing, conditioning and medicinal treatment shampoo	July, 1992	Lange
5264206	Nail lacquer with antimycotic activity, and a process for the preparation thereof	November, 1993	Bohn et al.
5346692	Nail lacquer for the treatment of onychomycosis	September, 1994	Wohlrab et al.
5356907	1-cycloalkylpyridones as analgesics	October, 1994	Clemence et al.
5395843	Pyridones	March, 1995	Clemence et al.
5494658	Antidandruff agents and cosmetic preparations	February, 1996	Hänel et al.
5510100	Oil-in-water emulsions containing an auto-emulsifiable composition based on a fatty alcohol and on an alkyl polyoside and a co-emulsifying agent	April, 1996	Picard et al.
5559130	Pyrrolidinyl pyridones for treating pain	September, 1996	Clemence et al.
5603939	Film-forming cosmetic composition based on a chlorinated graft copolymer resulting from the grafting of a chlorinated polyolefin and acrylic, styrene and/or vinyl type unsaturated monomers	February, 1997	Ser
5609854	Thickened and stabilized cosmetic emulsion compositions	March, 1997	Guerrero et al.
5612327	1α,24-(OH).sub.2 -cholecalciferol emulsion composition and method for treating psoriasis	March, 1997	Makino et al.
5650145	Dermatological/cosmetic compositions comprising antifungal and antibacterial compounds and reduction of hair loss therewith	July, 1997	Saint-Leger
5675013	1-hydroxy-6-substituted pyridine-2-ones and 1-hydroxy-6-substituted pyridine-2-thiones for biocidal use	October, 1997	Hani et al.
5683681	Cosmetic compositions for application to the nail	November, 1997	Ramin et al.
5753600	Liquid detergent composition	May, 1998	Kamegai et al.
5756108	Oily phase in an aqueous phase dispersion stabilized by cubic gel particles and method of making	May, 1998	Ribier et al.
5866105	Pharmaceutical composition	February, 1999	Richter et al.
6162420	Use of glyceryl triacetate for treating onychomycoses	December, 2000	Bohn et al.
6455551	Use of 1-hydroxy-2-pyridones for treating mucosa diseases which are difficult to treat	September, 2002	Kraemer et al.
6469033	Use of 1-hydroxy-2-pyridones for the treatment of skin diseases	October, 2002	Bohn et al.
20030086881	Antiinfective combinations and their use for the topical treatment of fungal infections of the toenails and fingernails	May, 2003	Bohn et al.

AU716208	April, 1998
CA2134293	April, 1995
CA2134304	April, 1995
DE3140954	May, 1983
DE3826914	February, 1990
EP0218410	April, 1987			Use of 1-hydroxy-2-pyridones in the treatment of acne.
EP0241918	October, 1987			1-Hydroxy-2-pyridinones, process for their preparation and medicines containing them, as well as intermediates formed by the preparation of 1-hydroxy-2-pyridinones.
EP0313305	April, 1989			Photoprotection compositions comprising chelating agents.
EP0381446	August, 1990			Oral antifungal compositions.
EP0515312	November, 1992			Pharmaceutical composition containing terbinafine as an anti-mycotic agent.
EP0646369	April, 1995			Cosmetic compositions comprising 1-hydroxy-2-pyridones as antidandruff and deodorant agents.
EP0649660	April, 1995			Pharmaceutical composition for parenteral, enteral and dermal administration of essentially insoluble drugs and process for their preparation.
EP0680745	November, 1995			Use of antifungals and or halogenated antibacterial agents for diminishing hair loss.
EP0771187	May, 1997			NOVEL COMBINATION PRODUCT COMPRISING AN ANTIFUNGAL AGENT AND CROTAMITON AS AN ANTIFUNGAL ACTIVITY ENHANCER AND DERMATOLOGICAL OR COSMETIC COMPOSITIONS COMPRISING SAME
FR2618068	January, 1989
FR2685638	July, 1993
FR2685867	July, 1993
FR2694694	February, 1994
GB2207051	January, 1989
GB2208149	March, 1989
HU202098	March, 1990
HU208007	July, 1993
JP6169721	April, 1986
JP95325488	August, 1995
WO/1987/002580	May, 1987			FILM-FORMING, PHARMACEUTICAL VEHICLES FOR APPLICATION OF MEDICAMENTS TO NAILS, PHARMACEUTICAL COMPOSITIONS BASED ON THOSE VEHICLES, AND METHODS OF USING SAME
WO/1994/005256	March, 1994			MILD, SUBSTANTIALLY COLORLESS SHAMPOO COMPOSITION
WO/1995/017165	June, 1995			TISSUE MOISTURIZING AND ANTIMICROBIAL COMPOSITIONS
WO/1996/002226	February, 1996			NOVEL COMBINATION PRODUCT COMPRISING AN ANTIFUNGAL AGENT AND CROTAMITON AS AN ANTIFUNGAL ACTIVITY ENHANCER AND DERMATOLOGICAL OR COSMETIC COMPOSITIONS COMPRISING SAME
WO/1996/013247	May, 1996			ANTIODOR, ANTIMICROBIAL AND PRESERVATIVE COMPOSITIONS AND METHODS OF USING SAME
WO/1996/019186	June, 1996			ANTIFUNGAL TREATMENT OF NAILS
WO/1996/029045	September, 1996			COMPOSITIONS FOR THE TREATMENT OF DANDRUFF
WO/1996/029056	September, 1996			TOPICALLY APPLIED PHARMACEUTICAL COMPOSITION, METHOD OF PREPARING IT AND ITS USE
WO/1997/020560	June, 1997			USE OF 1-HYDROXY-2-PYRIDONES FOR TREATING MUCOSA DISEASES WHICH ARE DIFFICULT TO TREAT
WO/1998/013009	April, 1998			USE OF 1-HYDROXY-2-PYRIDONE FOR THE TREATMENT OF SEBORRHEIC DERMATITIS
WO/1998/013043	April, 1998			USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SKIN DISEASES
WO/1998/013042	April, 1998			ANTIMYCOTIC GEL WITH HIGH ACTIVE SUBSTANCE RELEASE
WO/1999/039680	August, 1999			ANTIFUNGAL NAIL LACQUER AND METHOD USING SAME
WO/1999/049835	October, 1999			AN ACIDIFIED COMPOSITION FOR TOPICAL TREATMENT OF NAIL AND SKIN CONDITIONS

Yoshimasa et al., “The sebum lipid assimilation and the growth inhibition of Pityrosporum ovale (1st report), ” J. SCCJ, vol. 22(3), pp. 165-170 (1988).
Saint-Leger et al., “The role of the resident microflora in the pathogenesis of dandruff,” J. Soc. Cosmet. Chem., vol. 40, pp. 109-117 (1989).
H. Hänel et al., “Evaluation of Fungicidal Action in Vitro and in a Skin Model Considering the Influence of Penetration Kinetics of Various Standard Antimycotics,” Annals New York Academy of Sciences, 544:329-337 (1988).
P.C. Braga et al., “Inhibition of Candida albicans Adhesiveness to Human Buccal and Vaginal Cells by Sub-inhibitory Concentrations of Rilopirox,” Arzneim.-Forsch./Drug Res., 45(1):84-87 (1995).
H. Hänel et al., “A Comparison of Bifonazole and Ciclopiroxolamine: In Vitro, Animal, and Clinical Studies,” Mycoses 31(12):632-640 (1988).
W. Raether et al., “Rilopriox-a New Hydroxypyridone Antifungal with Fungicidal Properties,” Mycoses, 33(4):191-202 (1990).
H. Hanel et al., Treatment of seborrhoic eczema using an antimycotic with antiphlogistic properties, Mycoses 34(Suppl.):91-93 (1991).
R. Aly et al., “Common Superficial Fungal Infections in Patients with AIDS,” CID 22(Supp. 2):S128-S132 (1996).
E. Grosshans et al., “L'Eczema Seborrheique (La Pityrosporose),” Ann. Dermatol. Venereol., 115:79-86 (1988) (with English translation of abstract).
Martindale The Extra Pharmacopoeia 30th Ed., London The Pharmaceutical Press 1993, pp. 332, 1609.
Montana, et al., “A Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of Fungoid Tincture® in Patients with Distal Subungual Onychmycosis of the Toes,” Cutis, 53:313-316 (1994).
J. Shapiro et al., “Medicated Shampoos,” Clinics in Dermatology, 14:123-128 (1996).
Derwent Abstract of FR 2 685 638.
Derwent Abstract of WO 96/2226A1.
Japanese Abstract No. 07082126A, Mar. 28, 1995.
Derwent Abstract of EP 0 680 745 A2.
Derwent Abstract of EP 0 649 660 A2.
Derwent Abstract of EP 0 646 369 A1.
Derwent Abstract of FR 2 618 068.
Derwent Abstract of JP 61-69721.
Translation of EP 0 771 187.
Rivalland, P., “Evaluation of the Antifungal Activity of Two Derivatives and In Vivo Innocuity Test of Shampooings with Regard to Antidandruff Formulations,” Abstract, Int. J. Cosmet. Sci. (1994), vol. 16(2), pp. 77-83.
Abstract of FR 2 685 867 A1.
Abstract of FR 2 694 694 A1.
Translation of Thorel (FR 2 685 867 A1) with Certification of Translation (12 pages total).
Abrams et al., “Ciclopirox Olamine: A Hydroxypyridone Antifungal Agent,” Clinics In Dermatology, vol. 9, pp. 471-477 (1992).
Amos et al., “Clinical efficacy of Polytar AF (Fongitar) and Nizoral Scalp Treatments in Patients with Dandruff/Seborrhoeic Dermatitis,” Journal of Dermatological Treatment, vol. 5, pp. 127-130 (1994).
Corte et al., “Topische Anwendung einer 0.1%igen Ciclopiroxolamin-Lösung zur Behandlung der Pityriasis versicolor, Topical Application of a 0.1% Ciclopiroxolamine Solution for the Treatment of Pityriasis versicolor,” Mycoses, vol. 32, No. 4, pp. 200-203 (1989). (English Abstract).
Cullen et al., “Treatment of Tinea Versicolor with a New Antifungal Agent, Ciclopirox Olamine Cream 1%,” Clinical Therapeutics, vol. 7, No. 5, pp. 574-583 (1985).
Faergemann, J., “Pityriasis Versicolor,” Seminars in Dermatology, vol. 12, No. 4, pp. 276-279 (1993).
Plewig et al., “Seborrheic Dermatitis,” FitzPatrick's Dermatology in General Medicine, 5th Ed., Ch. 126, pp. 1-17 CD-Rom (1999).
Przekop et al., “Ciclopirox Olamine, An Antifungal Modulator of Neutrophil Function and Infiltrate in Cutaneous Inflammation,” J. Investigative Dermatology, vol. 102, No. 4, (SID Abstracts) p. 593 (1994).
Schofer, H., “Therapie des seborrhoischen Ekzems bei HIV-Infektion,” Forschung und Praxis, 98 Seite III (1990).
Shuster, S., “Dandruff, Seborrhoeic Dermatitis, and Pityrosporum Ovale,” Cosmetics and Toiletries, vol. 103, pp. 87-91 (1988).
“Scaly Dermatoses,” Handbook of Nonprescription Drugs, American Pharm. Assoc., Ch. 26, pp. 550-552 (1996).
“Seborrheic Dermatitis and Dandruff,” Manual of Dermatologic Therapeutics, 5th Ed., Ch. 29, pp. 164-167 (1995).

Webman, Edward J.

Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.

The invention claimed is:

1. A gel composition comprising: at least one compound chosen from 1-hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone and physiologically tolerable salts thereof; polyacrylic acid polymer; sodium dioctylsulfosuccinate; and 2-octyldodecanol; wherein the composition is not an emulsion.

2. A gel composition comprising: at least one compound chosen from 1-hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone and physiologically tolerable salts thereof; polyacrylic acid polymer; polyoxyethylene(20)sorbitan monostearate; and isopropyl myristate; wherein the composition is not an emulsion.

The present invention relates to a topically applicable antimycotic preparation having a high active compound release in the form of a gel preparation which contains at least one antimycotic substance from the hydroxypyridone class and at least one hydrophilic gel-forming agent.

For the topical treatment of mycoses, especially mycoses of the skin, various preparation forms of hydroxypyridone derivatives such as solutions, ointments and powders are already known. Optimum treatment of dermatomycoses, however, using the preparation forms of hydroxy-pyridones known until now is not unrestrictedly possible for the most diverse reasons.

Topically applicable liquid preparations in general include clear aqueous or aqueous-alcoholic solutions. They are either painted onto the skin surface or used for washing or baths. In particular, they are used in any skin regions which are covered by dense hair growth, since ointments or powders are not suitable for these areas. Moreover, they are used in those skin areas for which other pharmaceutical forms are not willingly used for cosmetic reasons, e.g. on the face or on highly mobile body sites (e.g. elbows, knee etc.).

The release rate of the active compound from solutions is generally high, since after application by evaporation of the vehicle constituents, a high concentration gradient between the preparation and the skin results, which in the end leads to a high absorption of active compound through the skin and thus to a high efficacy.

With respect to their applicational properties, solutions, however, are as less favorable, since on account of their liquid aggregate state they can only be handled with difficulty, in particular on the face, and a specific application to restricted skin areas is not possible.

Ointments or semisolid pharmaceutical preparation forms are administration forms which in general are spreadable in the temperature range between room temperature and skin temperature and thereby can be differentiated from the liquid administration forms and those with solid character. Based on the substance characteristics of the skin vehicle substances, ointments are in general understood as meaning anhydrous fatty bases or emulsions consisting of an oily and aqueous phase, which are stabilized by an emulsifier.

On account of their semisolid consistency, ointment preparations—in contrast to solutions—can be applied very specifically to restricted skin areas. Owing to the content of fatty constituents, however, the release of the lipophilic hydroxypyrrolidone derivatives from the ointment constituents is highly restricted. The success of treatment after ointment application is furthermore adversely affected by the fact that ointments do not usually leave behind a wipe-resistant film on the skin. On contact with the clothing or bed linen, the product applied can thus be easily removed again and is thus no longer available for successful therapy.

Powder preparations are primarily used for the adsorption of increased secretion and keeping the skin dry; a point which, in particular in the treatment of dermatomycoses, plays an important part. For practical reasons, the application of powder preparations is almost exclusively restricted to the treatment of mycosis pedis.

It has now been found that gel formulations of hydroxypyridone derivatives, which contain solvents and hydrophilic gel-forming agents and also customary formulation auxiliaries, make possible a high release of the active compound and thus an improved action due to the achievement of high concentrations of the active compound in the skin. The preparations according to the invention can furthermore be applied to the affected skin areas easily and specifically on account of their semisolid consistency, and moreover, exhibit the desired drying-out effect, particularly in the treatment of mycosis pedis.

The invention therefore relates to a pharmaceutical preparation comprising a hydrophilic gel-forming agent, water and a compound of the formula I
or a physiologically tolerable salt of the compound of the formula I, where R ¹ , R ² and R ³ , which are identical or different, are a hydrogen atom or alkyl having 1 to 4 carbon atoms, and R ⁴ is a saturated hydrocarbon radical having 6 to 9 carbon atoms.

A preferred pharmaceutical preparation is one where

• R ⁴ is a saturated hydrocarbon having 6 to 9 carbon atoms, one of the radicals R ¹ and R ³ is a hydrogen atom and the other is a hydrogen atom, methyl or ethyl and R ² is an alkyl radical having 1 or 2 carbon atoms.

A particularly preferred pharmaceutical preparation is one wherein the compound of the formula I contains a cyclic radical in the position R ⁴ .

Furthermore preferred is a pharmaceutical preparation wherein R ⁴ is a cyclohexyl radical or —CH ₂ —CH(CH ₃ )—CH ₂ —C(CH ₃ ) ₃ .

The term “saturated” in this case designates those radicals which contain no aliphatic multiple bonds, i.e. no ethylenic or acetylenic bonds.

Suitable compounds of the formula I which may be mentioned, for example, are

• 1-hydroxy-4-methyl-6-n-hexyl-, -6-iso-hexyl-, -6-n-heptyl- or -6-isoheptyl-2-pyridone, 1-hydroxy-4-methyl-6-octyl- or -6-isooctyl-2-pyridone, in particular as 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone, 1-hydroxy-4-methyl-6-cyclohexyl-2-pyridone, 1-hydroxy-4-methyl-6-cyclohexylmethyl- or -6-cyclohexyl-ethyl-2-pyridone, where the cyclohexyl radical can in each case also carry a methyl radical, 1-hydroxy-4-methyl-6-(2-bicyclo-[2.2.1]heptyl)-2-pyridone, 1-hydroxy-3,4-dimethyl-6-benzyl- or -6-dimethylbenzyl-2-pyridone and 1-hydroxy-4-methyl-6-(β-phenylethyl)-2-pyridone.

The invention furthermore relates to the use of the pharmaceutical preparation for the production of a pharmaceutical for the treatment and prophylaxis of dermatomycoses.

Using the pharmaceutical according to the invention, drastic healing can be achieved in the treatment of dermatomycoses. The pharmaceutical according to the invention is also suitable for prophylactic application against dermatomycoses.

The content of the compound of the formula I in the pharmaceutical preparation according to the invention is dependent on the structure of each compound of the formula I and thus on its release from the gel, its penetration behavior in the skin and its antimicrobial properties.

In the pharmaceutical preparation according to the invention, the compound of the formula I is in general contained in an amount from 0.05 to 2 percent by weight, preferably 0.1 to 1% by weight.

Possible gel-forming agents are native substances such as gelatin, pectin, carrageenan, agar, tragacanth and alginates, semisynthetic gel-forming agents such as cellulose ethers (methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, sodium carboxymethyl-cellulose), starch derivatives, pectin derivatives, fully synthetic gel-forming agents such as polyacrylates, polymethacrylates, polyvinyl alcohol, or mixtures thereof. Polyacrylates are particularly suitable. These gel-forming agents are employed in amounts from 0.3 to 2.0 parts by weight to 100 parts by weight of final product.

Suitable solvents are water and also all solvents miscible with water. Those suitable are, for example, alkanols such as ethanol or isopropyl alcohol, and also propylene glycol and dimethyl sulfoxide. One or more solvents can be employed in the preparation of the formulations according to the invention.

Suitable additional solubilizers for the pharmaceutical preparation according to the invention are:

• Benzyl alcohols, 2-octyldodecanol, adipates, propylene glycol and glycerol. These solubilizers are contained in the preparations according to the invention from 1 to 15 percent by weight (% by weight).

Suitable further auxiliaries are emulsifiers, wetting agents and spreading agents.

The preparations are prepared in a manner known per se by combining the individual components and—if necessary—further processing suited to the particular preparation.

The present invention is explained in greater detail by the following examples, but is not restricted to these. If not stated otherwise, the quantitative data relate to the weight.

EXAMPLE 1

A preparation according to the invention has the following composition:

1-Hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)pyrido ne	0.50%
Hydroxyethylcellulose	1.50%
Polyethylene glycol-7 glycerylcocoate	5.00%
1,2-propane glycol	10.00%
Isopropyl alcohol	20.00%
Demineralized water	63.00%

EXAMPLE 2

A preparation according to the invention has the following composition:

	1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone	1.00%
	Polyacrylic acid polymer
	(e.g. Carbomer 934 P)	0.70%
	Sodium hydroxide	0.20%
	Sodium dioctylsulfosuccinate	0.05%
	2-octyldodecanol	7.50%
	Isopropyl alcohol	25.00%
	Demineralized water	65.55%

EXAMPLE 3

A preparation according to the invention has the following composition:

	1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone	0.50%
	Polyacrylic acid polymer
	(e.g. Carbomer 940)	0.50%
	Sodium hydroxide	0.20%
	Polyoxyethylene(20)sorbitan monostearate	3.50%
	Isopropyl myristate	10.00%
	Ethanol	20.00%
	Demineralized water	65.30%

EXAMPLE 4

A preparation according to the invention has the following composition:

1-Hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)-pyrid one	1.00%
Hydroxypropylcellulose	1.00%
1,2-Propylene glycol	2.50%
Ethanol	20.00%
Demineralized water	75.50%

EXAMPLE 5

An ointment preparation from the prior art has the following composition:

	1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone	1.00%
	Petroleum jelly	20.00%
	Stearyl alcohol	15.00%
	2-Octyldodecanol	10.00%
	Polyoxyethylene(20)sorbitan monostearate	3.50%
	Sorbitan monostearate	1.50%
	Demineralized water	49.00%

EXAMPLE 6

Activity Testing

The active compound release of the pharmaceutical preparation according to the invention in a penetration model was tested using excised pig's skin.

The testing of the active compound release from the compositions according to the invention was carried out in a penetration model on excised pig's skin. Here, a conclusion is drawn indirectly on the active compound release from the compositions according to the invention via the determination of the penetration depth by means of a microbiological determination method:

Relatively large pieces of back skin were excised from slaughtered pigs before scalding the killed animals. The back skin was wrapped with moist paper and plastic film and deep frozen at −20° C. until the test.

Before the test, the skin surface was freed from fatty tissue, shaved and treated with isopropanol for 60 minutes for disinfection purposes. For each test batch a separate piece of skin (about 2×3 cm) was used. The skin surface was treated with preparations containing various compounds of formula I. After the end of the various action times (0.5, 1 and 4 hours), the products were removed from the skin surface by washing. In order to investigate the different penetration power of the active compounds—or the different release power of the preparations—the pieces of skin were stripped off 2×, 6× and 10× using Scotch film on, in each case, three adjacent tracks. Each track was then inoculated 10× in a punctiform manner with a suspension of Trichophyton mentagrophytes 100/25 (about 200 microconidia per inoculation point). The pieces of skin were then incubated at 28° C. for 7 days on water and agar with penicillin, streptomycin and cycloheximide addition. From the 4th day of incubation onwards, the result was daily read off macroscopically.

Results:

After a time of action of the active compound-containing gel preparations, according to Examples 1 to 4, of 4 hours, the pieces of skin are macroscopically fungus-free on all sections—in contrast to the corresponding placebo preparations.

For the active compound-containing ointment preparation not according to the invention, according to Example 5, which was prepared according to the prior art, the time of action of 4 hours is not sufficient to kill the macroconidia on the inoculated segments.